SCHEMBL4939348

SCHEMBL4939348

C[C@H](N)C(=O)N1CCCCC1C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 6/20 0.58
REN P00797 4/20 0.58
KDM4E B2RXH2 1/20 0.58
F2 P00734 1/20 0.58
LMNA P02545 1/20 0.58
LTA4H P09960 1/20 0.58
MAPT P10636 1/20 0.58
PEPD P12955 1/20 0.58
ALOX15 P16050 1/20 0.58
PTGS1 P23219 1/20 0.58
HTR2A P28223 1/20 0.58
PTGS2 P35354 1/20 0.58
HRH1 P35367 1/20 0.58
THPO P40225 1/20 0.58
PMP22 Q01453 1/20 0.58
HSD17B10 Q99714 1/20 0.58
ACE2 Q9BYF1 1/20 0.58
DPP4 P27487 3/20 0.53
FAP Q12884 2/20 0.53
DPP7 Q9UHL4 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4939337 1.00 ACE (0.58) ACERENKDM4EF2LMNA
SCHEMBL9439065 0.98 ACE (0.56) ACERENKDM4EF2LMNA
SCHEMBL9439063 0.98 ACE (0.56) ACERENKDM4EF2LMNA
SCHEMBL152403 0.95 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL593691 0.95 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL2115244 0.95 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL2115246 0.95 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL8316371 0.95 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL9164453 0.95 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL7271951 0.95 ACE (0.64) ACERENKDM4EF2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080081823-A1 PIPECOLIC ACID-CONTAINING ANTIDIABETIC COMPOSITIONS AJINOMOTO CO., INC. (JP) 2008-04-03 US disclosed
EP-1839661-A2 Pipecolic acid-containing antidiabetic compositions AJINOMOTO CO., INC. (JP) 2007-10-03 EP disclosed
CN-101045055-A Pipecolic acid-containing antidiabetic compositions AJINOMOTO KK (JP) 2007-10-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081823-A1 PIPECOLIC ACID-CONTAINING ANTIDIABETIC COMPOSITIONS GPR119, PIP5K1C, PIP4K2C ACE 3735/4885REN 1201/4885KDM4E 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.